A Phase 3 Multicenter Randomized Double- Blind Placebo- Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Recruiting
99 years or below
All
Phase 3
4 participants needed
1 Location

Brief description of study

The research study is being conducted to test the safety and tolerability (i.e., possible side effects) of an investigational drug called AL001 and to find out what effects AL001 has on the body. This is for people who have a confirmed progranulin gene mutation that causes frontotemporal dementia (FTD). Study particiants will need to have a spouse, family member, or friend participate in this study with them as a study partner. This person should have at least 5 hours of in-person contact with the study participant each week and will be responsible for providing information about memory and daily functioning of the study participant to the study doctor or study staff during study visits. The study partner must also agree to participate in this study by signing a separate Informed Consent Form.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All
Updated on 09 Apr 2021. Study ID: 844404

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.